Research ArticleStroke

An MD2-perturbing peptide has therapeutic effects in rodent and rhesus monkey models of stroke

See allHide authors and affiliations

Science Translational Medicine  09 Jun 2021:
Vol. 13, Issue 597, eabb6716
DOI: 10.1126/scitranslmed.abb6716

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A peptide for two strokes

Ischemic stroke and hemorrhagic stroke require different therapies. Unfortunately, the time required to identify the stroke subtype reduces the effectiveness of subsequent therapies. Toll-like receptor 4 (TLR4) signaling has been implicated in the pathophysiology of both types of stroke. Here, Fang et al. developed a peptide called Tat-CIRP able to inhibit TLR4 signaling by interfering with its accessory protein myeloid differentiation 2 (MD2). Tat-CIRP exerted neuroprotective effects in models of hemorrhagic and ischemic stroke in mice and reduced infarct volume in nonhuman primates without signs of toxicity. The results suggest that Tat-CIRP could be effective for treating both ischemic and hemorrhagic stroke subtypes.

View Full Text

Stay Connected to Science Translational Medicine